| Literature DB >> 20499296 |
Margot Joosen1, Monique Frings-Dresen, Judith Sluiter.
Abstract
BACKGROUND: Prolonged fatigue can cause physical, mental and occupational disability. Fatigue often persists because of a combination of biopsychosocial factors.Entities:
Mesh:
Year: 2011 PMID: 20499296 PMCID: PMC3088825 DOI: 10.1007/s12529-010-9099-4
Source DB: PubMed Journal: Int J Behav Med ISSN: 1070-5503
Characteristics of the three vocational rehabilitation interventions (VRIs)
| VRI 1 | VRI 2 | VRI 3 | |
|---|---|---|---|
| Target group | Patients with fatigue complaints and functional impairments | Workers with fatigue complaints and functional (work) impairments | Workers with fatigue complaints and functional (work) impairments |
| Recruitment strategies | Self referred | Referred by an occupational physician or benefits agency | Referred by an occupational physician or benefits agency |
| Financing of the intervention | By patients themselves | By the employer of the patient | By the employer of the patient |
| Overall goal | Reduce fatigue complaints and regain balance between activity and rest | Achieving a normal balance between daily life and work | Achieving a normal pattern of functioning including return-to-work |
| Duration | 18 weeks | 18 weeks (3 x 6 weeks) | 4, 5 or 6 weeks |
| Days | 3 times a week | 3, 2, 1 times a week | From 5 to 2 times a week |
| Level | Individual | Individual and group level | Group and individual level |
Fig. 1Flow-chart of patients through the study
Characteristics of the patients of VRI1, VRI2 and VRI3
| VRI 1 | VRI 2 | VRI 3 | |
|---|---|---|---|
| Mean (SD) or Freq. (%) | Mean (SD) or Freq. (%) | Mean (SD) or Freq. (%) | |
| Intervention completed ( | 30 | 29 | 41 |
| Age | 47 (8.1) | 45 (12.1) | 45 (10.4) |
| Male | 5 (17%) | 16 (55%) | 24 (59%) |
| Female | 25 (83%) | 13 (45%) | 17 (41%) |
| Severe fatigue (CIS score >76)a | 83% | 90% | 95% |
| Duration of fatigue complaints in years | 5.8 (5.6) | 3.0 (3.6) | 3.7 (4.7) |
| Duration functional impairments in years | 4.0 (4.7) | 2.5 (3.2) | 3.4 (5.4) |
| Employment status | |||
| Paid job, fully at work | 10 (33%) | 11 (38%) | 20 (49%) |
| Paid job, partly on sick leave | 8 (27%) | 13 (45%) | 15 (37%) |
| Paid job, fully on sick leave | 6 (20%) | 2 (7%) | 3 (7%) |
| No paid job | 6 (20%) | 3 (10%) | 3 (7%) |
aCIS score above 76 was set as the cut-off point for chronic fatigue and increased risk of sickness absence due to fatigue [36]
Process evaluation: content, aims of components, frequency of dose in protocol (average number of sessions per patient), dose delivered (incl. range) and completeness (%) of the VRIs
| Session type | Components/sessions | Aim | Freq. dose protocol (range)a | Freq. dose delivered (range) | Completeness % (range) | ||
|---|---|---|---|---|---|---|---|
| VRI 1 | 18 weeks: 3 times a week | Exercise test | Exercise test | Examine physical condition (basis for workout scheme) | 3 (3) | 2 (1–6) | 59 (33–100) |
| Physical training | Progressive workout scheme (incl. warm-up, aerobic training, muscle strength training, cool-down) | Reconditioning, improve aerobic fitness | 51 (36–54) | 29 (13–48) | 57 (28–94) | ||
| Relaxation | Relaxation techniques (prior and after each physical training) | Relaxation/stress reduction | 51 (36–54) | 26 (10–47) | 51 (27–94) | ||
| Breathing exercises (visual feedback) | Relaxation | 51 (36–54) | 25 (9–45) | 49 (25–92) | |||
| Psychological | Informal conversations about cognition of illness and training. | Improve coping with the illness/increase knowledge sickness behaviour and training theory | Not in protocol | 12 (3–36) | 100% of the patients | ||
| VRI 2 | 18 weeks (3 times 6): 3, 2, 1 times a weeks | Assessment | Intake procedure (exercise test, psychological examination, goal setting) | Examine physical and mental condition (basis for workout scheme and session delivered) | 3 (0) | 3 (2–4) | 92 (67–100) |
| Physical training | Progressive workout scheme (warm-up, aerobic training, muscle strength training, cool-down) | Reconditioning, improve aerobic fitness | 36 (0) | 30 (9–37) | 83 (25–100) | ||
| Psychological/cognitive behavioural | Breathing, awareness and relaxation | Body awareness/stress reduction | 5 (0) | 3 (0–5) | 59 (0–100) | ||
| Group coaching module | Improve coping strategies | 4 (0) | 2 (0–7) | 88 (0–100) | |||
| Psychologist (individual counselling, cognitive therapy (e.g. RET)) | Stress reduction, improve coping strategies | Max 10b | 3 (0–11) | 73 (0–100) | |||
| Energy engineering (individual) | Physical coaching, body awareness, relaxation | Max 10b | 4 (0–10) | 100 (0) | |||
| Education | Increase knowledge about illness, sickness behaviour and training theory | 8 (0) | 4 (2–8) | 47 (25–100) | |||
| Return-to-work | Work and Organisation (discussing strengths/weaknesses, preparing for return-to-work, work experiences) | Return-to-work | Max 10b | 5 (0–11) | 100 (0) | ||
| VRI 3 | 4, 5, 6, weeks | Physical (training) | Graded activity training | Reconditioning, body knowledge | 12 (5–25) | 12 (1–28) | 85 (20–100) |
| Unrestricted moving | Body knowledge | 3 (1–4) | 2 (1–4) | 89 (33–100) | |||
| Cognitive behavioural | Cognitive therapy (e.g. RET) | Stress reduction, improve coping strategies | 7 (4–11) | 7 (2–13) | 88 (29–100) | ||
| Education | Increase knowledge about illness and sickness behaviour | 2 (1–3) | 2 (0–6) | 90 (0–100) | |||
| Partner session | Increase knowledge about illness and sickness behaviour | 1 (0–1) | 0.2 (0–1) | 28 (0–100)c | |||
| Energy engineering | Body awareness, relaxation | 1 (1–3) | 2 (1–3) | 96 (50–100) | |||
| Evaluation | Goal setting (personal goals), evaluating progress | 2 (2–3) | 2 (0–5) | 87 (0–100) | |||
| Return-to-work | Work (preparing for return-to-work, workplace visit) | Return-to-work | 5 (2–7) | 4 (0–10) | 74 (0–100) | ||
| Follow-up (work experiences) | Return-to-work, improve coping strategies | 3 (2–4) | 3 (0–7) | 76 (0–100) | |||
Completeness: average of dose delivered in percentage compared with dose in protocol per individual
aFrequency ranges because of differences in modules or duration of the intervention, determined individually post-intake
bNumber of sessions was individually determined during the intervention, but with a maximum of ten sessions
cNot an accurate figure because of lack of information about number of sessions in the protocol, individually determined
Mean scores (95% confidence intervals) on degree of fatigue parameters, perceived work ability and work participation at t0 (baseline), t1 (at completion of the intervention) and t2 (3 months after completion) in three VRIs and p values for the differences over the three measurements
| Degree of fatigue | Work participation | Work ability | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue (CIS) | Work-related fatigue (VBBA) | Vitality (SF-36) | Return-to-work (%) | Perceived work ability (WAI) | |||||||||||
| 20–140 (scale) | 0–100 (scale) | 0–100 (scale) | 0–100 | 0–10 (scale) | |||||||||||
|
| 30 | 29 | 41 | 24 | 25 | 40 | 30 | 29 | 41 | 24 | 26 | 38 | 30 | 29 | 41 |
| VRI 1 | |||||||||||||||
| t0, M (95% CI) | 98 (88.9–106.6) | 68 (54.8–81.7) | 32 (27.5–36.2) | 63 (45.5–81.0) | 4 (2.8–4.7) | ||||||||||
| t1, M (95% CI) | 67 (58.3–76.1)*** | 47 (34.4–60.5)** | 55 (49.2–61.4)*** | 76 (61.2–91.6)* | 6 (5.0–6.9)*** | ||||||||||
| t2, M (95% CI) | 62 (52.6–71.0)*** | 46 (33.0–58.8)** | 59 (52.3–66.3)*** | 81 (68.7–94.0)** | 6 (5.5–7.4)*** | ||||||||||
| Overall | <.001 | .001 | <.001 | .008 | <.001 | ||||||||||
| VRI 2 | |||||||||||||||
| t0, M (95% CI) | 107 (99.2–115.3) | 78 (64.8–91.5) | 34 (27.1–39.9) | 31 (16.6–45.9) | 3 (2.2–3.8) | ||||||||||
| t1, M (95% CI) | 64 (50.7–76.6)*** | 33 (19.1–46.2)*** | 62 (53.7–70.6)*** | 67 (51.5–83.3)*** | 7 (5.8–7.3)*** | ||||||||||
| t2, M (95% CI) | 66 (52.8–79.6)*** | 40 (24.2–55.5)** | 59 (50.2–68.1)*** | 80 (65.6–95.0)*** | 7 (5.7–7.6)*** | ||||||||||
| Overall | <.001 | <.001 | <.001 | <.001 | <.001 | ||||||||||
| VRI 3 | |||||||||||||||
| t0, M (95% CI) | 107 (101.6–111.6) | 81 (73.8–87.4) | 30 (26.4–34.6) | 31 (21.0–41.0) | 3 (2.9–4.0) | ||||||||||
| t1, M (95% CI) | 78 (71.3–85.0)*** | 55 (45.3–64.4)*** | 51 (45.7–55.6)*** | 57 (46.7–66.9)*** | 6 (5.0–6.1)*** | ||||||||||
| t2, M (95% CI) | 75 (65.6–84.2)*** | 52 (39.8–63.2)*** | 52 (45.3–59.1)*** | 84 (73.5–94.5)*** | 6 (5.6–7.0)*** | ||||||||||
| Overall | <.001 | <.001 | <.001 | <.001 | <.001 | ||||||||||
*p < .02; **p < .01; ***p < .001 (post-hoc analysis (Bonferroni adjustments: unadjusted p values x 2) within subjects (compared with t0))
Mean scores (95% confidence intervals) on physical functioning, mental health, social functioning and mean scores (standard deviations) on heart rate variability at t0 (baseline), t1 (at completion of the intervention) and t2 (3 months after completion) in three VRIs and p values for the differences over the three measurements
| Physical functioning | Mental Health | Social functioning | Heart rate variability | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning (SF-36) | Physical role limitation (SF-36) | Mental health (SF-36) | Emotional role limitation (SF-36) | Social functioning (SF-36) | HF power (ms) | ||||||||||||
| 0–100 | 0–100 | 0–100 | 0–100 | 0–100 | |||||||||||||
|
| 30 | 29 | 41 | 30 | 29 | 41 | 30 | 29 | 41 | 30 | 29 | 41 | 30 | 29 | 41 | 29 | 26 |
| VRI 1 | |||||||||||||||||
| t0, M (95% CI) | 74 (68.0–81.0) | 14 (4.2–24.2) | 57 (50.7–63.4) | 47 (29.5–63.8) | 56 (52.2–60.3) | 64 (SD = 79.5) | |||||||||||
| t1, M (95% CI) | 86 (79.5–92.6)*** | 61 (44.0–78.4)*** | 71 (65.1–76.4)*** | 87 (77.0–97.8)*** | 57 (53.6–60.2) | 164 (SD = 295.4) | |||||||||||
| t2, M (95% CI) | 86 (79.6–92.8)*** | 64 (46.3–80.9)*** | 73 (67.5–77.6)*** | 75 (60.7–89.1)** | 53 (47.3–58.5) | Not measured | |||||||||||
| Overall | <.001 | <.001 | <.001 | .001 | .442 | .044 | |||||||||||
| VRI 2 | |||||||||||||||||
| t0, M (95% CI) | 62 (54.3–70.4) | 9 (.2–18.2) | 56 (48.7–63.0) | 45 (28.1–61.5) | 54 (51.0–56.8) | 27 (SD = 31.2) | |||||||||||
| t1, M (95% CI) | 83 (75.8–90.4)*** | 52 (36.3–68.4)*** | 75 (69.1–81.2)*** | 67 (50.5–84.1) | 54 (51.5–57.4) | 71 (SD = 122.9) | |||||||||||
| t2, M (95% CI) | 82 (73.5–90.6)*** | 61 (45.0–77.6)*** | 72 (63.9–80.2)*** | 62 (45.0–79.5) | 51 (47.9–53.9) | Not measured | |||||||||||
| Overall | <.001 | <.001 | <.001 | .098 | .196 | .038 | |||||||||||
| VRI 3 | |||||||||||||||||
| t0, M (95% CI) | 66 (59.2–73.0) | 13 (3.1–22.6) | 50 (44.5–55.6) | 28 (15.9–41.1) | 51 (48.1–54.4) | Not measured | |||||||||||
| t1, M (95% CI) | 81 (74.4–88.3)*** | 41 (27.8–54.1)*** | 64 (58.4–69.6)*** | 53 (40.6–66.1)** | 55 (53.0–57.8)* | Not measured | |||||||||||
| t2, M (95% CI) | 82 (75.2–89.1)*** | 53 (39.4–67.0)*** | 68 (62.7–73.8)*** | 71 (58.5–84.0)*** | 56 (53.8–58.2)* | Not measured | |||||||||||
| Overall | <.001 | <.001 | <.001 | <.001 | .022 | ||||||||||||
*p < .02; **p < .01; ***p < .001 (post-hoc analysis (Bonferroni adjustments: unadjusted p values x 2) within subjects (compared with t0))